Xeris Biopharma Holdings, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a XERS research report →
Range $14 – $16
Price Chart
About the company
Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia.
- CEO
- John Shannon
- IPO
- 2018
- Employees
- 435
- HQ
- Chicago, IL, US
Get TickerSpark's AI analysis on XERS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $3.10B
- P/E
- -428.43
- Fwd P/E
- 40.40
- PEG
- 0.04
- P/S
- 8.52
- P/B
- 63.72
- EV/EBITDA
- 123.02
- Div Yield
- 0.00%
- Gross Margin
- 84.44%
- Op Margin
- 12.70%
- Net Margin
- -1.76%
- ROE
- -39.52%
- ROIC
- 15.85%
Latest fiscal year · YoY change
- Revenue
- $291.85M+43.7%
- Gross Profit
- $238.43M+43.4%
- Op Income
- $24.90M
- Net Income
- $554.00K+101.0%
- EPS
- $0.00+100.9%
- OCF Growth
- +177.4%
- FCF Growth
- +173.8%
- 52W High
- $17.28
- 52W Low
- $5.25
- 50D MA
- $11.10
- 200D MA
- $8.02
- Beta
- 0.84
- RSI (14)
- 81
- Avg Volume
- 2.84M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Xeris posted a strong third quarter, driven by rapid Recorlev growth, a rebound in Gvoke demand, and steady KEVEYIS gains, while raising 2026 and 2030 revenue targets.· November 5, 2026
- Total revenue rose 44% year over year to $107.2 million, with net product revenue up 43% to $106.3 million.
- Recorlev was the main growth engine, with net revenue of $71.5 million, up 93% year over year.
- Gvoke prescriptions grew 5% year over year, but reported revenue was pressured by a $4 million one-time gross-to-net adjustment in Medicaid.
- KEVEYIS delivered $13 million in net revenue, up 9% year over year, and management highlighted continued durability.
- Xeris raised full-year 2026 revenue guidance to $395 million-$405 million and lifted its 2030 total revenue outlook to more than $1 billion.
Third-quarter total revenue was $107.2 million, up 44% year over year and 16% sequentially. Net product revenue was $106.3 million, up 43% or $32.2 million year over year. Recorlev net revenue was $71.5 million, up 93% or $34.6 million year over year, while Gvoke net revenue was $21.7 million versus $25.2 million a year ago and KEVEYIS net revenue was $13 million, up 9% year over year. Gross margin was 88% versus 85% in the prior-year period, Adjusted EBITDA was $30.8 million, up 77% year over year, and net income was $11.3 million versus $0.6 million last year. For 2026, management raised total revenue guidance to $395 million-$405 million, kept gross margin guidance unchanged, lowered expected R&D expense growth to about $15 million versus 2025, and raised expected SG&A growth to about $60 million versus 2025. The company also now expects more than $1 billion in total revenue by 2030, up from a prior $750 million outlook.
John Shannon said the quarter put Xeris on a “new growth curve,” with momentum broadening across Recorlev, Gvoke, and KEVEYIS. He emphasized that Recorlev is benefiting from expanded screening for hypercortisolism and from the commercial team’s January expansion, while also saying the company expects momentum to continue into 2027 and beyond. He was notably upbeat about the company’s long-term trajectory, saying the updated outlook is grounded in current execution rather than aspiration.
Steve Pieper focused on the financial execution behind the quarter, highlighting 44% revenue growth, 88% gross margin, and $30.8 million of Adjusted EBITDA. He said gross margin improved due to favorable product mix, R&D rose to $11.1 million due to XP-8121 investment, and SG&A rose to $64.1 million mainly from higher personnel-related commercial costs. On guidance, he said R&D growth should be about $15 million versus 2025, lower than prior expectations because of timing of XP-8121 spending, while SG&A growth is now expected to be about $60 million as the company deliberately invests in near-term opportunities.
Analysts pressed on whether Recorlev’s growth is sustainable into 2027, and management said the expanded field force plus broader screening and diagnosis dynamics should keep driving growth. They also asked about access, and management said Recorlev still faces typical prior authorization and medical-necessity hurdles, with no near-term change expected. Questions on the higher 2030 revenue outlook and incremental cash deployment led management to say all three brands should contribute, while excess cash would first go toward commercial assets and XP-8121, then potential business development aligned with its footprint. On KEVEYIS, management said new resources were just deployed and will mainly affect Q4 and 2027, and that in this ultra-rare market there is no reliable way to measure share, though Xeris believes it is the only company actively finding and starting new patients.
The call’s positive case is that Xeris is showing broad-based operating leverage, with 44% revenue growth, expanding gross margin, and strong Adjusted EBITDA growth. Management is increasingly confident that Recorlev, Gvoke, and KEVEYIS can all contribute to growth, while XP-8121 adds a longer-term pipeline upside with a stated peak sales potential of $1 billion-$3 billion.
Management acknowledged that Recorlev still depends on ongoing prior-auth and medical-necessity work, and access dynamics are not expected to improve quickly. Gvoke’s revenue was still below prior-year levels despite better prescription demand because of a one-time gross-to-net adjustment, and KEVEYIS remains in a tiny ultra-rare market where share is hard to measure and new investments will take time to ramp.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 94.9%
- Shares Outstanding
- 182.70M
- Float Shares
- 173.47M
of shares held by institutions
251 13F filers
Buy/sell ratio 0.13. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 14.66M | ▲ 133.76K |
| Vanguard Group Inc | 11.19M | ▲ 1.36M |
| D. E. Shaw & Co., Inc. | 7.98M | ▲ 175.40K |
| Vanguard Capital Management LLC | 7.71M | ▲ 370.13K |
| State Street Corp | 5.57M | ▲ 752.96K |
| Geode Capital Management, LLC | 4.57M | ▼ 147.43K |
| Nuveen, LLC | 4.14M | ▼ 243.25K |
| Vanguard Portfolio Management LLC | 2.65M | ▲ 22.67K |
| Rosalind Advisors, Inc. | 2.58M | ▼ 326.33K |
| Morgan Stanley | 2.58M | ▲ 243.43K |
| Qube Research & Technologies Ltd | 2.48M | ▼ 416.93K |
| Jpmorgan Chase & Co | 2.38M | ▲ 1.32M |
Held by 244 ETFs
Biggest fund positions in XERS by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 5, 26 | McCulloch Kevin | sell | 25,000 |
| Nov 2, 26 | Pieper Steven | sell | 5,000 |
| Nov 2, 26 | Hecht Beth | sell | 25,000 |
| Nov 2, 26 | McCulloch Kevin | sell | 15,000 |
| Nov 2, 26 | Taddese Menassie | other | 31,499 |
| Nov 2, 26 | Taddese Menassie | other | 22,365 |
| Nov 2, 26 | Taddese Menassie | other | 0 |
| Oct 1, 26 | Pieper Steven | sell | 5,000 |
| Oct 1, 26 | McCulloch Kevin | sell | 15,000 |
| Oct 1, 26 | Hecht Beth | sell | 16,666 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our XERS coverage
Recent articles, reports, and earnings notes.
No research on XERS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate XERS report →Which Healthcare ETF Is Best for the Long Term: State Street’s XPH or Invesco’s PBE?
fool.com · Nov 15
Xeris Biopharma: Time For A Pause
seekingalpha.com · Nov 12
Drug Makers or Biotech Bets: Which ETF Is the Better Buy, State Street’s XPH or First Trust’s FBT?
fool.com · Nov 11
Xeris Biopharma Q3 Earnings Call Highlights
marketbeat.com · Nov 6
Xeris Biopharma (NASDAQ:XERS) Reaches New 12-Month High on Better-Than-Expected Earnings
defenseworld.net · Nov 6
Xeris Biopharma Holdings, Inc. (XERS) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 5
Xeris Biopharma (XERS) Surpasses Q3 Earnings and Revenue Estimates
zacks.com · Nov 5
Xeris Biopharma (XERS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
zacks.com · Nov 5
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.